Bifeprunox in the Treatment of Schizophrenia

Solvay

Status and phase: Completed; Phase 3

Conditions: Schizophrenia

Treatments: Drug: bifeprunox

Study type: Interventional

Funder types: Industry

Identifiers

NCT00193687

S154.3.002

Details and patient eligibility

About

Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia. Extension to study S154.3.001.

Enrollment: 986 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

diagnosis of schizophrenia, understand nature of study, able to be managed in out-patient setting for long-term bifeprunox treatment

Exclusion criteria

current primary diagnosis other than schizophrenia, suicide risk, diagnosis or history of substance abuse, uncontrolled hypertension

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)